You are here

  • Home
  • Archive
  • Volume 77, Issue Suppl 2
  • FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients

Article info

Article menu

Download PDFPDF

FRIDAY, 15 JUNE 2018
Systemic sclerosis, myositis and related syndromes – etiology, pathogenesis and animal models
FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients
Free

Authors

Citation

Ah Kioon M, Lindsay R, Chen J, et al
FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients
Annals of the Rheumatic Diseases 2018;77:731-732.

Publication history

  • First published June 12, 2018.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions